3-Ethyl-5-methoxy-4-hydroxybenzaldehyde | 125722-35-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-Ethyl-5-methoxy-4-hydroxybenzaldehyde
• 英文别名: 3-Ethyl-4-hydroxy-5-methoxybenzaldehyde
• CAS: 125722-35-2
• 化学式: C₁₀H₁₂O₃
• 分子量: 180.203
• InChiKey: PRRISPVSROGWFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-噻吩乙酸 、 3-Ethyl-5-methoxy-4-hydroxybenzaldehyde 在 哌啶 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 生成 2-Ethyl-6-methoxy-4-(2-thiophen-2-yl-vinyl)-phenol
  参考文献：
  名称：

  Effect of structure on potency and selectivity in 2,6-disubstituted-4-(2-arylethenyl)phenol lipoxygenase inhibitors

  摘要：

  A series of 2,6-disubstituted 4-(2-arylethenyl)phenols with potent human neutrophil 5-lipoxygenase (5-LO) inhibiting activity (IC50S in the 10(-7) M range) and weaker human platelet cyclooxygenase (CO) inhibiting activity (IC50S in the 10(-6) M range) is described. This series evolved from the chemical modification of an antiinflammatory dual CO/5-LO inhibitor, 2,6-di-tert-butyl-4-[2-(3-pyridyl)ethenyl]phenol (BI-L-93 BS). The potency and selectivity for 5-LO inhibition is greatly influenced by the nature of the substituents in the 2- and 6-positions. Other structure-activity relationships that determine relative 5-LO and CO potency are discussed. In vivo activity against antigen-induced leukotriene-mediated bronchoconstriction and cell influx in guinea pigs is presented. Representatives of the series are active when administered at 30 mg/kg ip.

  DOI：

  10.1021/jm00169a010
• 作为产物：
  描述：

  6-乙基邻甲氧基苯酚 在 乌洛托品 作用下， 以 溶剂黄146 为溶剂， 生成 3-Ethyl-5-methoxy-4-hydroxybenzaldehyde
  参考文献：
  名称：

  Compounds for inhibiting the biosynthesis of lipoxygenase-derived metabolites of arachidonic acid

  摘要：

  公开号：

  EP0334119B1

文献信息

• [EN] IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS IMIDAZO[2,1]THIAZOL-3-ONE UTILES COMME AGENTS DE DIAGNOSTIC DE LA MALADIE D'ALZHEIMER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014026881A1

  公开（公告）日：2014-02-20

  The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula (I) wherein the variables are as defined in the claims. It has been shown that the present compounds may be used for binding and imaging tau aggregates and related b-sheet aggregates including besides others beta-amyloid aggregates or alpha-synuclein aggregates, especially for use in binding and imaging tau aggregates in Alzheimer patients.

  该发明涉及式(I)中变量定义如权利要求中的咪唑[2,1-b]噻唑-3-酮衍生物。已经证明，这些化合物可用于结合和成像tau聚集体和相关的b-折叠聚集体，包括除其他外beta-淀粉样蛋白聚集体或α-突触核蛋白聚集体，特别是用于结合和成像阿尔茨海默病患者中的tau聚集体。
• Imidazo[2,1]thiazol-3-one derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150157739A1

  公开（公告）日：2015-06-11

  The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula wherein the variables are defined herein, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. It has been shown that the present compounds may be used for binding and imaging tau aggregates and related b-sheet aggregates including besides others beta-amyloid aggregates or alpha-synuclein aggregates, especially for use in binding and imaging tau aggregates in Alzheimer's patients.

  本发明涉及以下式子的咪唑[2,1-b]噻唑-3-酮衍生物，其中变量在此定义，或者其药学上可接受的酸加成盐，外消旋混合物或其对应的对映体和/或光学异构体。已经证明，这些化合物可以用于结合和成像tau聚集体和相关的β-折叠聚集体，包括除其他外的β-淀粉样聚集体或α-突触核蛋白聚集体，特别适用于在阿尔茨海默病患者中结合和成像tau聚集体。
• IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2885306B1

  公开（公告）日：2016-06-01
• US5480674A
  申请人：——

  公开号：US5480674A

  公开（公告）日：1996-01-02
• Effect of structure on potency and selectivity in 2,6-disubstituted-4-(2-arylethenyl)phenol lipoxygenase inhibitors
  作者：Edward S. Lazer、Hin Chor Wong、Craig D. Wegner、Anne G. Graham、Peter R. Farina

  DOI：10.1021/jm00169a010

  日期：1990.7

  A series of 2,6-disubstituted 4-(2-arylethenyl)phenols with potent human neutrophil 5-lipoxygenase (5-LO) inhibiting activity (IC50S in the 10(-7) M range) and weaker human platelet cyclooxygenase (CO) inhibiting activity (IC50S in the 10(-6) M range) is described. This series evolved from the chemical modification of an antiinflammatory dual CO/5-LO inhibitor, 2,6-di-tert-butyl-4-[2-(3-pyridyl)ethenyl]phenol (BI-L-93 BS). The potency and selectivity for 5-LO inhibition is greatly influenced by the nature of the substituents in the 2- and 6-positions. Other structure-activity relationships that determine relative 5-LO and CO potency are discussed. In vivo activity against antigen-induced leukotriene-mediated bronchoconstriction and cell influx in guinea pigs is presented. Representatives of the series are active when administered at 30 mg/kg ip.